QDI Stock Chart & Stats
CHF186.24
CHF0.00(0.00%)
―
--
Day’s Range― - ―
52-Week RangeCHF186.24 - CHF198.46
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
CHF21.75B
Enterprise ValueCHF29.88K
Total Cash (Recent Filing)CHF626.00M
Total Debt (Recent Filing)CHF6.38B
Price to Earnings (P/E)25.6
Beta1.11
Next Earnings
Oct 27, 2026EPS Estimate
2.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)9.54
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio1.43
Price to Book (P/B)2.69
Price to Sales (P/S)1.75
P/FCF Ratio14.17
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF203.49Price Target Upside― Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)9.1
Revenue Forecast (FY)CHF9.78B
Bulls Say, Bears Say
Bulls Say
Revenue And Volume GrowthStrong revenue and requisition growth indicates expanding diagnostic demand and successful customer acquisition. Volume gains from health-system relationships add recurring specimen flow, while organic growth shows momentum beyond newly added partnerships.
Advanced Diagnostics ExpansionRegulatory approval and oncology distribution expand Quest’s specialized testing reach and commercial opportunity. Broader access to high-complexity assays can improve test mix, deepen provider relationships, and support revenue per requisition over time.
Strong Cash GenerationLarge absolute operating and free cash flows give Quest resources to fund laboratory technology, automation, capital spending, acquisitions, and shareholder returns. This supports resilience and strategic flexibility despite softer conversion trends.
Bears Say
Margin NormalizationProfitability remains solid but materially below its prior peak, indicating less operating leverage and limited evidence that exceptional margins are sustainable. Mix changes, investment spending, and normalized demand may continue constraining margin expansion.
Reimbursement UncertaintyPotential changes to government reimbursement and ACA coverage economics could pressure realized pricing and revenue growth across Quest’s broad testing base. Delayed or unfavorable policy outcomes would make planning and margin protection more difficult.
Leverage And Weaker Cash ConversionModerate leverage is manageable, but sizable debt reduces flexibility if reimbursement or operating conditions weaken. Concurrently lower cash-flow conversion and declining free cash flow could limit capacity for investment, acquisitions, or shareholder distributions.
Quest Diagnostics News
QDI FAQ
What was Quest Diagnostics’s price range in the past 12 months?
Quest Diagnostics lowest stock price was CHF186.24 and its highest was CHF198.46 in the past 12 months.
What is Quest Diagnostics’s market cap?
Quest Diagnostics’s market cap is CHF21.75B.
When is Quest Diagnostics’s upcoming earnings report date?
Quest Diagnostics’s upcoming earnings report date is Oct 27, 2026 which is in 60 days.
How were Quest Diagnostics’s earnings last quarter?
Quest Diagnostics released its earnings results on Jul 23, 2026. The company reported CHF2.543 earnings per share for the quarter, beating the consensus estimate of CHF2.301 by CHF0.242.
Is Quest Diagnostics overvalued?
According to Wall Street analysts Quest Diagnostics’s price is currently Undervalued.
Does Quest Diagnostics pay dividends?
Quest Diagnostics does not currently pay dividends.
What is Quest Diagnostics’s EPS estimate?
Quest Diagnostics’s EPS estimate is 2.34.
How many shares outstanding does Quest Diagnostics have?
Currently, no data Available
What happened to Quest Diagnostics’s price movement after its last earnings report?
Quest Diagnostics reported an EPS of CHF2.543 in its last earnings report, beating expectations of CHF2.301. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Quest Diagnostics?
Currently, no hedge funds are holding shares in CH:QDI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quest Diagnostics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
CHF203.49 (― Upside)
CHF203.49 (― Upside)
Blogger Sentiment
Bullish
CH:QDI Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
34.88%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
6.07%
Trailing 12-Months
Company Description
Quest Diagnostics
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
QDI Company Deck
QDI Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented strong operational and commercial momentum: double-digit revenue growth, robust volume expansion, notable diagnostic and commercial milestones (Haystack MRD approval, Flatiron integration), meaningful adjusted EPS growth (+19.1%) and a raised full-year guide. Offsetting these positives are short-term margin pressures (70 bps headwind in Q2 from Nova ramp, Corewell/Fresenius mix and deferred compensation), higher expected H2 costs (fuel and Nova), and regulatory reimbursement risk (PAMA uncertainty and a ~30 bps ACA headwind). On balance, the positives (top-line strength, EPS improvement, raised guidance, product/partnership milestones, and productivity/automation investments) significantly outweigh the headwinds.View all CH:QDI earnings summariesQDI Revenue Breakdown
97.73% Diagnostic Information Services
2.27% DS businesses
